Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev












Signal Accounts for Members
All Signal Accounts
All Contests



Italy Retail Sales MoM (SA) (Oct)A:--
F: --
P: --
Euro Zone Employment YoY (SA) (Q3)A:--
F: --
P: --
Euro Zone GDP Final YoY (Q3)A:--
F: --
P: --
Euro Zone GDP Final QoQ (Q3)A:--
F: --
P: --
Euro Zone Employment Final QoQ (SA) (Q3)A:--
F: --
P: --
Euro Zone Employment Final (SA) (Q3)A:--
F: --
Brazil PPI MoM (Oct)A:--
F: --
P: --
Mexico Consumer Confidence Index (Nov)A:--
F: --
P: --
Canada Unemployment Rate (SA) (Nov)A:--
F: --
P: --
Canada Labor Force Participation Rate (SA) (Nov)A:--
F: --
P: --
Canada Employment (SA) (Nov)A:--
F: --
P: --
Canada Part-Time Employment (SA) (Nov)A:--
F: --
P: --
Canada Full-time Employment (SA) (Nov)A:--
F: --
P: --
U.S. Personal Income MoM (Sept)A:--
F: --
P: --
U.S. PCE Price Index YoY (SA) (Sept)A:--
F: --
P: --
U.S. PCE Price Index MoM (Sept)A:--
F: --
P: --
U.S. Personal Outlays MoM (SA) (Sept)A:--
F: --
P: --
U.S. Core PCE Price Index MoM (Sept)A:--
F: --
P: --
U.S. Core PCE Price Index YoY (Sept)A:--
F: --
P: --
U.S. UMich 5-Year-Ahead Inflation Expectations Prelim YoY (Dec)A:--
F: --
P: --
U.S. Real Personal Consumption Expenditures MoM (Sept)A:--
F: --
P: --
U.S. 5-10 Year-Ahead Inflation Expectations (Dec)A:--
F: --
P: --
U.S. UMich Current Economic Conditions Index Prelim (Dec)A:--
F: --
P: --
U.S. UMich Consumer Sentiment Index Prelim (Dec)A:--
F: --
P: --
U.S. UMich 1-Year-Ahead Inflation Expectations Prelim (Dec)A:--
F: --
P: --
U.S. UMich Consumer Expectations Index Prelim (Dec)A:--
F: --
P: --
U.S. Weekly Total Rig CountA:--
F: --
P: --
U.S. Weekly Total Oil Rig CountA:--
F: --
P: --
U.S. Unit Labor Cost Prelim (SA) (Q3)--
F: --
P: --
U.S. Consumer Credit (SA) (Oct)A:--
F: --
P: --
China, Mainland Foreign Exchange Reserves (Nov)--
F: --
P: --
China, Mainland Exports YoY (USD) (Nov)--
F: --
P: --
China, Mainland Imports YoY (CNH) (Nov)--
F: --
P: --
China, Mainland Imports YoY (USD) (Nov)--
F: --
P: --
China, Mainland Imports (CNH) (Nov)--
F: --
P: --
China, Mainland Trade Balance (CNH) (Nov)--
F: --
P: --
China, Mainland Exports (Nov)--
F: --
P: --
Japan Wages MoM (Oct)--
F: --
P: --
Japan Trade Balance (Oct)--
F: --
P: --
Japan Nominal GDP Revised QoQ (Q3)--
F: --
P: --
Japan Trade Balance (Customs Data) (SA) (Oct)--
F: --
P: --
Japan GDP Annualized QoQ Revised (Q3)--
F: --
China, Mainland Exports YoY (CNH) (Nov)--
F: --
P: --
China, Mainland Trade Balance (USD) (Nov)--
F: --
P: --
Germany Industrial Output MoM (SA) (Oct)--
F: --
P: --
Euro Zone Sentix Investor Confidence Index (Dec)--
F: --
P: --
Canada Leading Index MoM (Nov)--
F: --
P: --
Canada National Economic Confidence Index--
F: --
P: --
U.S. Dallas Fed PCE Price Index YoY (Sept)--
F: --
P: --
U.S. 3-Year Note Auction Yield--
F: --
P: --
U.K. BRC Overall Retail Sales YoY (Nov)--
F: --
P: --
U.K. BRC Like-For-Like Retail Sales YoY (Nov)--
F: --
P: --
Australia Overnight (Borrowing) Key Rate--
F: --
P: --
RBA Rate Statement
RBA Press Conference
Germany Exports MoM (SA) (Oct)--
F: --
P: --
U.S. NFIB Small Business Optimism Index (SA) (Nov)--
F: --
P: --
Mexico Core CPI YoY (Nov)--
F: --
P: --
Mexico 12-Month Inflation (CPI) (Nov)--
F: --
P: --
Mexico PPI YoY (Nov)--
F: --
P: --


No matching data
Latest Views
Latest Views
Trending Topics
Top Columnists
Latest Update
White Label
Data API
Web Plug-ins
Affiliate Program
View All

No data
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
(a) Full name of discloser | BlackRock, Inc. |
(b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. | N/A |
(c) Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree | Avadel Pharmaceuticals plc |
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) | |
(e) Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure | 03 December 2025 |
(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" | N/A |
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security (Note 3) | $0.01 ordinary shares | ||||
Interests | Short positions | ||||
Number | % | Number | % | ||
(1) Relevant securities owned and/or controlled | 6,823,149 | 6.95% | 2,934 | 0.00% | |
(2) Cash-settled derivatives | 0 | 0.00% | 4,268 | 0.00% | |
(3) Stock-settled derivatives (including options) and agreements to purchase/ sell | 0 | 0.00% | 0 | 0.00% | |
Total | 6,823,149 | 6.95% | 7,202 | 0.00% | |
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security | $0.01 ordinary shares |
Purchase/sale | Sale |
Number of securities | 1,230 |
Price per unit (Note 5) | USD 21.3600 |
(b) Cash-settled derivative transactions
Class of relevant security
Product
description
e.g. CFD
Nature of dealing
e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position
Number of
reference
securities
(Note 6)
Price
per unit
(Note 5)
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product
description e.g. call
option
Writing, purchasing, selling, varying
etc.
Number of
securities to which option relates (Note 6)
Exercise
price per
unit
Type
e.g. American,
European etc.
Expiry
date
Option money
paid/
received per unit
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/
exercised against
Number of securities
Exercise price per unit (Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class of relevant security | Nature of dealing e.g. subscription, conversion, exercise | Details | Price per unit (if applicable) (Note 5) |
$0.01 ordinary shares | Stock on Loan | 76,800 | N/A |
$0.01 ordinary shares | Return of Stock on Loan | 17,900 | N/A |
$0.01 ordinary shares | Transfer in of Shares | 19,482 | N/A |
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
(c) Attachments
Is a Supplemental Form 8 attached?
NO
Date of disclosure | 04 December 2025 |
Contact name | Jana Blumenstein |
Telephone number | +44 20 7743 3650 |
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
NOTES ON FORM 8.3
1. See the definition of "connected fund manager" in Rule 2.2 of Part A of the Rules.
2. See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.
3. See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.
4. See the definition of "dealing" in Rule 2.1 of Part A of the Rules.
5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.
6. See Rule 2.5(d) of Part A of the Rules.
7. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPPKQBBKBDDDBK
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
(a) Full name of discloser | Bank of America Corporation |
(b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. | |
(c) Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree | AVADEL PHARMACEUTICALS PLC |
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) | |
(e) Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure | 03/12/2025 |
(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" | No |
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security (Note 3) | 0.01 ordinary shares | |||
Interests | Short positions | |||
Number | % | Number | % | |
(1) Relevant securities owned and/or controlled | 2,804,362 | 2.879% | 1,065,284 | 1.094% |
(2) Cash-settled derivatives | 141,124 | 0.145% | 786,245 | 0.807% |
(3) Stock-settled derivatives (including options) and agreements to purchase/ sell | 0 | 0.000% | 0 | 0.000% |
Total | 2,945,486 | 3.024% | 1,851,529 | 1.901% |
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security | Purchase/sale | Number of securities | Price per unit (Note 5) |
USD 0.01 common | Purchase | 60 | 21.35 USD |
USD 0.01 common | Purchase | 12 | 21.355 USD |
USD 0.01 common | Purchase | 3 | 21.356667 USD |
USD 0.01 common | Purchase | 124 | 21.36 USD |
USD 0.01 common | Purchase | 7 | 21.37 USD |
USD 0.01 common | Purchase | 55 | 21.372546 USD |
USD 0.01 common | Purchase | 24 | 21.38 USD |
USD 0.01 common | Purchase | 6 | 21.39 USD |
USD 0.01 common | Purchase | 35 | 21.4 USD |
USD 0.01 common | Purchase | 4 | 21.405 USD |
USD 0.01 common | Purchase | 22 | 21.35 USD |
USD 0.01 common | Purchase | 3,755 | 21.355 USD |
USD 0.01 common | Purchase | 7,885 | 21.36 USD |
Class of relevant security | Purchase/sale | Number of securities | Price per unit (Note 5) |
USD 0.01 common | Sale | 18 | 21.35 USD |
USD 0.01 common | Sale | 42 | 21.355 USD |
USD 0.01 common | Sale | 3 | 21.356667 USD |
USD 0.01 common | Sale | 128 | 21.36 USD |
USD 0.01 common | Sale | 22560 | 21.364301 USD |
USD 0.01 common | Sale | 4 | 21.365 USD |
USD 0.01 common | Sale | 3 | 21.366667 USD |
USD 0.01 common | Sale | 25 | 21.37 USD |
USD 0.01 common | Sale | 55 | 21.372546 USD |
USD 0.01 common | Sale | 4 | 21.375 USD |
USD 0.01 common | Sale | 56 | 21.38 USD |
USD 0.01 common | Sale | 2 | 21.39 USD |
USD 0.01 common | Sale | 11 | 21.4 USD |
USD 0.01 common | Sale | 40 | 21.36 USD |
(b) Cash-settled derivative transactions
Class of relevant security | Product description e.g. CFD | Nature of dealing e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position | Number of reference securities (Note 6) | Price per unit (Note 5) USD |
USD 0.01 common | Swaps | Reducing a short position | 11,713 | 21.3629 USD |
USD 0.01 common | Swaps | Reducing a short position | 458 | 21.3629 USD |
USD 0.01 common | Swaps | Reducing a short position | 1,170 | 21.3629 USD |
USD 0.01 common | Swaps | Increasing a long position | 348 | 21.3629 USD |
USD 0.01 common | Swaps | Reducing a short position | 1,786 | 21.3629 USD |
USD 0.01 common | Swaps | Reducing a short position | 1,846 | 21.3629 USD |
USD 0.01 common | Swaps | Reducing a short position | 1,049 | 21.3629 USD |
USD 0.01 common | Swaps | Reducing a short position | 4,190 | 21.3629 USD |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security | N/A |
Product description e.g. call option | N/A |
Writing, purchasing, selling, varying etc. | N/A |
Number of securities to which option relates (Note 6) | N/A |
Exercise price per unit | N/A |
Type e.g. American, European etc. | N/A |
Expiry date | N/A |
Option money paid/ received per unit | N/A |
(ii) Exercise
Class of relevant security | N/A |
Product description e.g. call option | N/A |
Exercising/ exercised against | N/A |
Number of securities | N/A |
Exercise price per unit (Note 5) | N/A |
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class of relevant security | N/A |
Nature of dealing e.g. subscription, conversion, exercise | N/A |
Details | N/A |
Price per unit (if applicable) (Note 5) | N/A |
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
(c) Attachments
Is a Supplemental Form 8 attached?
No
Date of disclosure | 04/12/2025 |
Contact name | Kamil Dziedzic |
Telephone number | +353 86 168 4821 |
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPLZLFBELLFFBV
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader | GOLDMAN SACHS & CO. LLC |
Company dealt in | AVADEL PHARMACEUTICALS PLC |
Class of relevant security to which the dealings being disclosed relate (Note1) | USD 0.01 ordinary shares |
Date of dealing | 03 December 2025 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Long | Short | |||
Number | (%) | Number | (%) | |
(1) Relevant securities | 937,042 | (0.96) | 499,947 | (0.51) |
(2) Derivatives (other than options) | 63,546 | (0.06) | 63,843 | (0.06) |
(3) Options and agreements to purchase/sell | 0 | (0.00) | 0 | (0.00) |
Total | 1,000,588 | (1.02) | 563,790 | (0.57) |
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security: | Long | Short | ||
Number | (%) | Number | (%) | |
(1) Relevant securities | ||||
(2) Derivatives (other than options) | ||||
(3) Options and agreements to purchase/sell | ||||
Total | ||||
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale | Number of relevant securities | Price per unit (Note 4) |
Purchase | 100 | 21.3500 USD |
Purchase | 100 | 21.3500 USD |
Purchase | 100 | 21.3550 USD |
Purchase | 100 | 21.3550 USD |
Purchase | 927 | 21.3550 USD |
Purchase | 100 | 21.3550 USD |
Purchase | 100 | 21.3550 USD |
Purchase | 127 | 21.3550 USD |
Purchase | 100 | 21.3550 USD |
Purchase | 100 | 21.3550 USD |
Sale (Borrow Partial Return) | 11,700 | N/A |
Sale (Borrow Full Return) | 31,600 | N/A |
Purchase (Loan Full Return) | 423 | N/A |
Purchase (Loan Full Return) | 265 | N/A |
Purchase (Borrow New) | 1,177 | N/A |
Sale (Borrow Full Return) | 1,177 | N/A |
Purchase (Borrow New) | 3,000 | N/A |
Purchase (Borrow New) | 1,500 | N/A |
Purchase (Borrow New) | 72,900 | N/A |
Purchase (Borrow New) | 3,000 | N/A |
Purchase (Borrow New) | 1,177 | N/A |
Sale (Borrow Partial Return) | 49 | N/A |
Sale (Borrow Full Return) | 55,800 | N/A |
Purchase (Borrow New) | 7,000 | N/A |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 5) | Number of relevant securities (Note 6) | Price per unit (Note 4) |
CFD | Reducing a long position | 76 | 21.3630 USD |
CFD | Reducing a long position | 1,480 | 21.3706 USD |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name,e.g. call option
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise price
Type, e.g. American, European etc.
Expiry date
Option money paid/received per unit (Note 4)
(ii) Exercising
Product name,e.g. call option
Number of securities
Exercise price per unit (Note 4)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature of transaction (Note 7)
Details
Price per unit (if applicable) (Note 4)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
NONE
Is a Supplemental Form 8 attached? (Note 9) YES
Date of disclosure | 04 December 2025 |
Contact name | Papa Lette and Andrzej Szyszka |
Telephone number | +33(1) 4212 1459 / +48(22) 317 4817 |
Name of offeree/offeror with which connected | AVADEL PHARMACEUTICALS PLC |
Nature of connection (Note 9) | Advisor to Offeree |
SUPPLEMENTAL FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
OPEN POSITIONS (Note 1)
Product name,e.g. call option | Written or purchased | Number of relevant securities to which the option or derivative relates | Exercise price (Note 2) | Type, e.g. American, European etc. | Expiry date |
Swap | Sold | 84 | 0.0000 | N/A | 17/12/2025 |
Swap | Purchased | 33,762 | 0.0000 | N/A | 20/01/2026 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rules 8 and 38.5 of the Rules. If in doubt, consult the Panel.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPUPGQAPUPAGGC
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader | (GS) GOLDMAN SACHS INTERNATIONAL |
Company dealt in | AVADEL PHARMACEUTICALS PLC |
Class of relevant security to which the dealings being disclosed relate (Note1) | USD 0.01 ordinary shares |
Date of dealing | 03 December 2025 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Long | Short | |||
Number | (%) | Number | (%) | |
(1) Relevant securities | 53 | (0.00) | 1,128 | (0.00) |
(2) Derivatives (other than options) | 0 | (0.00) | 0 | (0.00) |
(3) Options and agreements to purchase/sell | 0 | (0.00) | 0 | (0.00) |
Total | 53 | (0.00) | 1,128 | (0.00) |
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security: | Long | Short | ||
Number | (%) | Number | (%) | |
(1) Relevant securities | ||||
(2) Derivatives (other than options) | ||||
(3) Options and agreements to purchase/sell | ||||
Total | ||||
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale | Number of relevant securities | Price per unit (Note 4) |
Sale (Borrow Full Return) | 423 | N/A |
Purchase (Loan Full Return) | 1,177 | N/A |
Sale (Loan New) | 1,177 | N/A |
Sale (Borrow Full Return) | 265 | N/A |
Sale (Loan New) | 1,177 | N/A |
Purchase (Loan Partial Return) | 49 | N/A |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD
Nature of transaction (Note 5)
Number of relevant securities (Note 6)
Price per unit (Note 4)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name,e.g. call option
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise price
Type, e.g. American, European etc.
Expiry date
Option money paid/received per unit (Note 4)
(ii) Exercising
Product name,e.g. call option
Number of securities
Exercise price per unit (Note 4)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature of transaction (Note 7)
Details
Price per unit (if applicable) (Note 4)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
NONE
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 04 December 2025 |
Contact name | Papa Lette and Andrzej Szyszka |
Telephone number | +33(1) 4212 1459 / +48(22) 317 4817 |
Name of offeree/offeror with which connected | AVADEL PHARMACEUTICALS PLC |
Nature of connection (Note 9) | Advisor to Offeree |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPUPGMAPUPAGGC
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
(a) Full name of discloser | Janus Henderson Group plc |
(b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. | |
(c) Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree | Avadel Pharmaceuticals plc |
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) | |
(e) Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure | 03 December 2025 |
(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" | N/A |
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Ap28
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security (Note 3) | $0.01 ordinary shares | |||
Interests | Short positions | |||
Number | % | Number | % | |
(1) Relevant securities owned and/or controlled | 3,756,867* | 3.86% | ||
(2) Cash-settled derivatives | ||||
(3) Stock-settled derivatives (including options) and agreements to purchase/ sell | ||||
Total | 3,756,867* | 3.86% | ||
*Janus Henderson Group Plc does not have discretion regarding voting decisions in respect 69,093 shares that are included in the total above.
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security | Purchase/sale | Number of securities | Price per unit (Note 5) |
€0.01 ordinary shares | Sale | 296 | USD 21.381841 |
€0.01 ordinary shares | Purchase | 23 | USD 21.360000 |
Ap29
(b) Cash-settled derivative transactions
Class of
relevant
security
Product
description
e.g. CFD
Nature of dealing
e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position
Number of
reference
securities
(Note 6)
Price
per unit
(Note 5)
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of
relevant
security
Product
description e.g. call
option
Writing, purchasing, selling, varying
etc.
Number
of
securities
to which
option
relates
(Note 6)
Exercise
price per
unit
Type
e.g.
American,
European
etc.
Expiry
date
Option
money
paid/
received per unit
(ii) Exercise
Class of
relevant
security
Product
description
e.g. call
option
Exercising/
exercised
against
Number of
securities
Exercise
price per
unit
(Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class of
relevant
security
Nature of dealing
e.g. subscription,
conversion, exercise
Details
Price per unit (if
applicable)
(Note 5)
Ap30
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
(c) Attachments
Is a Supplemental Form 8 attached?
No
Date of disclosure | 04 December 2025 |
Contact name | John Baker |
Telephone number | +44 207 818 3064 |
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
Ap31
NOTES ON FORM 8.3
1. See the definition of "connected fund manager" in Rule 2.2 of Part A of the Rules.
2. See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.
3. See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.
4. See the definition of "dealing" in Rule 2.1 of Part A of the Rules.
5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.
6. See Rule 2.5(d) of Part A of the Rules.
7. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPKZMGZMDVGKZM
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features

FastBull Membership
Not yet
Purchase
Log In
Sign Up